Pyxis Oncology Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	16.15	0	0	0	0	0
Cost of Revenue	0.48	0	0	0	0	0
Gross Profit	15.67	0	0	0	0	0
Selling, General & Admin	31.8	32.61	37.35	18.66	3.85	1.66
Research & Development	50.71	49.59	86.13	51.05	9.05	1.22
Operating Expenses	82.52	82.2	123.48	69.72	12.89	2.88
Operating Income	-66.85	-82.2	-123.48	-69.72	-12.89	-2.88
Other Expense / Income	-9.04	-8.41	-2.76	6.26	-0.07	-0.11
Pretax Income	-57.8	-73.79	-120.72	-75.98	-12.83	-2.77
Net Income	-57.8	-73.79	-120.72	-75.98	-12.83	-2.77
Shares Outstanding (Basic)	51	40	33	8	1	4
Shares Outstanding (Diluted)	51	40	33	8	1	4
Shares Change	45.08%	20.80%	288.93%	724.14%	-75.88%	-
EPS (Basic)	-1.36	-1.85	-3.65	-8.95	-12.45	-0.65
EPS (Diluted)	-1.36	-1.85	-3.65	-8.95	-12.45	-0.65
Free Cash Flow	-67.14	-77.44	-95.73	-35.87	-11.57	-2.24
Free Cash Flow Per Share	-1.31	-1.94	-2.90	-4.22	-11.22	-0.52
Gross Margin	97.06%	-	-	-	-	-
Operating Margin	-414.02%	-	-	-	-	-
Profit Margin	-358.00%	-	-	-	-	-
Free Cash Flow Margin	-415.80%	-	-	-	-	-
EBITDA	-54.27	-71.2	-118.88	-74.72	-11.99	-2.77
EBITDA Margin	-336.12%	-	-	-	-	-
Depreciation & Amortization	3.53	2.59	1.84	1.25	0.83	0
EBIT	-57.8	-73.79	-120.72	-75.98	-12.83	-2.77
EBIT Margin	-358.00%	-	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).